These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Fractionation of factor VIII and IX--an overview. Johnson AJ; Mathews RW; Fulton AJ Scand J Haematol Suppl; 1984; 40():513-24. PubMed ID: 6433474 [No Abstract] [Full Text] [Related]
3. To what extent can plasma supply for factor VIII production, be obtained within the frame of a blood component program? Högman CF Scand J Haematol Suppl; 1984; 40():485-90. PubMed ID: 6433469 [No Abstract] [Full Text] [Related]
5. Factor VIII usage in the Wisconsin Hemophilia Program; factor VIII usage in hemophilia. Lange D; Lazerson J Wis Med J; 1982 Feb; 81(2):28-31. PubMed ID: 6803446 [No Abstract] [Full Text] [Related]
6. Factor VIII production and usage in Hungary. Elödi S; Hollán SR Scand J Haematol Suppl; 1984; 40():491-7. PubMed ID: 6433470 [No Abstract] [Full Text] [Related]
7. Obtention production and use of factor VIII in Costa Rica. Cordero R; Montero C Scand J Haematol Suppl; 1984; 40():509-11. PubMed ID: 6433473 [No Abstract] [Full Text] [Related]
8. Production of antihemophilic factor in France. Allain JP Scand J Haematol Suppl; 1984; 40():499-503. PubMed ID: 6433471 [No Abstract] [Full Text] [Related]
10. Factor VIII supply and demand. Aronstam A Br Med J; 1980 Jun; 280(6230):1532-3. PubMed ID: 6770955 [No Abstract] [Full Text] [Related]
11. Letter: Commercial and NHS factor VIII concentrates. Cash JD Br Med J; 1976 Jan; 1(6003):221. PubMed ID: 1247788 [No Abstract] [Full Text] [Related]
12. Companies try different plans for same clotting factor product. Thompson CA Am J Health Syst Pharm; 2001 Jan; 58(1):16, 20. PubMed ID: 11194129 [No Abstract] [Full Text] [Related]
13. Observations from Global Survey 2001: an emerging database for progress. Evatt BL Haemophilia; 2002 Mar; 8(2):153-6. PubMed ID: 11952853 [No Abstract] [Full Text] [Related]
14. Factor VIII international units and reference materials. Bangham DR; Brozović M Thromb Diath Haemorrh; 1974 Mar; 31(1):3-11. PubMed ID: 4836134 [No Abstract] [Full Text] [Related]
15. Coagulation factor VIII concentrates and the marketplace. Cash JD Lancet; 1988 Jun; 1(8597):1270. PubMed ID: 2897528 [No Abstract] [Full Text] [Related]
16. Report of the Subcommittee on Human Factor 8 (AHF) Preparations. Wagner RH Thromb Diath Haemorrh Suppl; 1967; 26():371-5. PubMed ID: 6064867 [No Abstract] [Full Text] [Related]
17. Psychosocial issues surrounding the general or restricted use of recombinant factor VIII: hemophilia clinic perspective. McDonald JR Transfus Med Rev; 1992 Oct; 6(4):277-9. PubMed ID: 1421829 [No Abstract] [Full Text] [Related]
18. Proceedings: Factor VIII replacement in the treatment of haemophilia A--a simple illustration of a need-supply-demand spiral. Spencely M; Cash JD Br J Prev Soc Med; 1974 Feb; 28(1):71. PubMed ID: 4816606 [No Abstract] [Full Text] [Related]
19. A regional redistribution programme for the optimal management of clotting factor concentrates prescribed by haemophilia treatment centres. Crymble S; Anderson M; Travas A; Floros G; Teitel J Transfus Med; 2013 Oct; 23(5):370-2. PubMed ID: 23763626 [No Abstract] [Full Text] [Related]